. 2014 Mar 20;8(2):198–215. doi: 10.1007/s12072-014-9523-y

Table 1.

Patient demographics and baseline characteristics of 17 enrolled RCTs in this meta-analysis

First author	Year	Study center	Group	No of patients (n)	Gender (M/F)	Mean age (year)	Concomitant disease (n)					MELD score
First author	Year	Study center	Group	No of patients (n)	Gender (M/F)	Mean age (year)	Diabetes	Hypertension	CMV	EBV	Metabolic disease	MELD score
Comparison of Tac-based regimen with steroid or not (Sect. I)
Langrehr [25]	2002	University of Berlin, Germany	Tac + steroid	15
Langrehr [25]	2002	University of Berlin, Germany	Tac + MMF	15
Pelletier [26]	2005	University of Michigan, USA	Tac + MMF + steroid	36	28/8	53.0						18.0
Pelletier [26]	2005	University of Michigan, USA	Tac + MMF	36	25/11	55.0						17.0
Margarit [27]	2005	Universidad Autònoma Barcelona, Spain	Tac + steroid	32	25/7	56.0	5	6
Margarit [27]	2005	Universidad Autònoma Barcelona, Spain	Tac	28	18/10	57.0	6	3
Reggiani [17]	2005	Instituto di Ricovero e Cura a Caraterre Scientifico (IRCCS) Policlinico San Matteo, Italy	Tac + MMF + steroid	18	13/5	50.4
Reggiani [17]	2005		Tac + MMF	12	8/4	49.7
Junge [28]	2005	Charité Berlin Campus Virchow Klinikum, Germany	Tac + steroid	14
Junge [28]	2005	Charité Berlin Campus Virchow Klinikum, Germany	Tac + MMF	16
Chen [9]	2007	Tongji Medical College, China	Tac + MMF + steroid	26	0/26	47.4
Chen [9]	2007	Tongji Medical College, China	Tac + MMF	28	1/27	45.7
Vivarelli [29]	2007	University of Bologna, Italy	Tac + steroid	16		58.9	5					16.0
Vivarelli [29]	2007	University of Bologna, Italy	Tac	23		57.2	7					15.0
Manousou [30]	2009	University College London, UK	Azathioprine + steroid + Tac	49		50.0	13
Manousou [30]	2009	University College London, UK	Tac	54		48.9	13
Weiler [31]	2010	Hospital of Johannes Gutenberg University Mainz, Germany	Tac + steroid	54	36/18	53.5	10	10			0
Weiler [31]	2010	Hospital of Johannes Gutenberg University Mainz, Germany	Tac	56	38/18	53.6	11	6			2
Comparison of Tac-based regimen with induction agents or not (Sect. II)
Eason [32]	2003	Ochsner Clinic Foundation, New Orleans, USA	Tac + MMF + steroid	59
Eason [32]	2003	Ochsner Clinic Foundation, New Orleans, USA	RATG + Tac + MMF	60
Boillot [33]	2005	Hospital Edouard Herriot, France	Tac + steroid	347	238/109	51.0	55		248	237	2
Boillot [33]	2005	Hospital Edouard Herriot, France	Daclizumab + Tac	351	239/112	50.9	57		240	236	7
Spada [34]	2006	University of Pittsburgh Medical Center, Italy	Tac + steroid	36	15/21	2.8			20	11	3
Spada [34]	2006	University of Pittsburgh Medical Center, Italy	Basiliximab + Tac	36	18/18	2.9			19	12	2
Humar [35]	2007	University of Minnesota Minneapolis, USA	Tac + MMF + steroid	83		51.8						23.0
Humar [35]	2007	University of Minnesota Minneapolis, USA	Basiliximab + Tac + MMF	83		52.3						28.0
Kato [36]	2007	University of Miami School of Medicine, USA	Tac/MMF + steroid	39	29/10	50.2						16.5
Kato [36]	2007	University of Miami School of Medicine, USA	Daclizumab + Tac/MMF	31	21/10	52.4						14.6
Gras [37]	2008	Luc University Clinics, Université Catholique de Louvain, Belgium	Tac + steroid	34	16/18	2.0					4
Gras [37]	2008		Basiliximab + Tac	50	27/23	1.7					4
Foroncewicz [18]	2009	Medical University of Warsaw, Poland	Tac + steroid	18	10/8	41.8
Foroncewicz [18]	2009	Medical University of Warsaw, Poland	Daclizumab + Tac	7	5/2	43.3
Klintmalm [38]	2011	Baylor University Medical Center, USA	Tac + MMF + steroid	72	54/18	51.6
Klintmalm [38]	2011	Baylor University Medical Center, USA	Daclizumab + Tac + MMF	146	105/41	51.3

CMV cytomegalovirus, EBV Epstein-Barr virus, MELD model for end-stage liver disease, MMF mycophenolate mofetil, RATG rabbit antithymocyte globulin, Tac tacrolimus